KR102873380B1 - H4 길항제 화합물 - Google Patents

H4 길항제 화합물

Info

Publication number
KR102873380B1
KR102873380B1 KR1020217014805A KR20217014805A KR102873380B1 KR 102873380 B1 KR102873380 B1 KR 102873380B1 KR 1020217014805 A KR1020217014805 A KR 1020217014805A KR 20217014805 A KR20217014805 A KR 20217014805A KR 102873380 B1 KR102873380 B1 KR 102873380B1
Authority
KR
South Korea
Prior art keywords
compound
methyl
mmol
pyrazole
cas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217014805A
Other languages
English (en)
Korean (ko)
Other versions
KR20210079318A (ko
Inventor
질스 알버트 브라운
마일즈 스튜어트 콘그래브
배리 존 테오볼드
샬롯 필드하우스
니젤 알란 스웨인
마크 픽워쓰
지오바니 보테고니
Original Assignee
넥세라 파마 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥세라 파마 유케이 리미티드 filed Critical 넥세라 파마 유케이 리미티드
Publication of KR20210079318A publication Critical patent/KR20210079318A/ko
Application granted granted Critical
Publication of KR102873380B1 publication Critical patent/KR102873380B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217014805A 2018-10-19 2019-10-21 H4 길항제 화합물 Active KR102873380B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1817047.2A GB201817047D0 (en) 2018-10-19 2018-10-19 H4 antagonist compounds
GB1817047.2 2018-10-19
PCT/GB2019/052997 WO2020079457A1 (en) 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds

Publications (2)

Publication Number Publication Date
KR20210079318A KR20210079318A (ko) 2021-06-29
KR102873380B1 true KR102873380B1 (ko) 2025-10-23

Family

ID=64453795

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217014805A Active KR102873380B1 (ko) 2018-10-19 2019-10-21 H4 길항제 화합물

Country Status (13)

Country Link
US (2) US12234227B2 (cg-RX-API-DMAC10.html)
EP (1) EP3867248B1 (cg-RX-API-DMAC10.html)
JP (1) JP7532353B2 (cg-RX-API-DMAC10.html)
KR (1) KR102873380B1 (cg-RX-API-DMAC10.html)
CN (1) CN113272297B (cg-RX-API-DMAC10.html)
AU (1) AU2019360428B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007372A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116628A1 (cg-RX-API-DMAC10.html)
ES (1) ES3058587T3 (cg-RX-API-DMAC10.html)
GB (1) GB201817047D0 (cg-RX-API-DMAC10.html)
MX (1) MX2021004280A (cg-RX-API-DMAC10.html)
SG (1) SG11202103133QA (cg-RX-API-DMAC10.html)
WO (1) WO2020079457A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
GB202019667D0 (en) * 2020-12-14 2021-01-27 Heptares Therapeutics Ltd H4 antagonist comnpounds
KR102655210B1 (ko) * 2021-03-26 2024-04-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
WO2022232259A1 (en) * 2021-04-28 2022-11-03 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof
EP4421067A4 (en) * 2021-10-19 2026-01-14 Unimatec Co Ltd PYRAZOLE COMPOUND CONTAINING FLUORIDE AND ITS PRODUCTION PROCESS
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000169475A (ja) 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd ピラゾ―ル誘導体およびその塩
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
WO2007072163A2 (en) 2005-12-20 2007-06-28 Pfizer Limited Pyrimidine derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573377B1 (en) * 1998-07-24 2003-06-03 Daiichi Pharmaceuticals Co., Ltd. Pyrazole derivatives and salts thereof
EP2066645A2 (en) 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
CL2008000467A1 (es) 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
WO2009068512A1 (en) 2007-11-30 2009-06-04 Palau Pharma, S. A. 2 -amino-pyrimidine derivatives as histamine h4 antagonists
PE20091524A1 (es) 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
RU2489430C2 (ru) 2007-12-21 2013-08-10 Палау Фарма, С.А. Производные 4-аминопиримидина
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
TW201035078A (en) 2009-03-20 2010-10-01 Incyte Corp Substituted heterocyclic compounds
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
JP5781537B2 (ja) 2009-12-23 2015-09-24 メディシス ファーマシューティカル コーポレイション ヒスタミンｈ４受容体アンタゴニストとしてのアミノアルキルピリミジン誘導体
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
JP2019525929A (ja) 2016-07-28 2019-09-12 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｐａｒｋｉｎ酵素機能の小分子活性化因子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000169475A (ja) 1998-07-24 2000-06-20 Dai Ichi Seiyaku Co Ltd ピラゾ―ル誘導体およびその塩
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
WO2007072163A2 (en) 2005-12-20 2007-06-28 Pfizer Limited Pyrimidine derivatives
JP2009520019A (ja) 2005-12-20 2009-05-21 ファイザー・リミテッド ピリミジン誘導体

Also Published As

Publication number Publication date
JP2022507013A (ja) 2022-01-18
EP3867248A1 (en) 2021-08-25
US20210300906A1 (en) 2021-09-30
WO2020079457A1 (en) 2020-04-23
KR20210079318A (ko) 2021-06-29
CA3116628A1 (en) 2020-04-23
BR112021007372A2 (pt) 2021-07-20
GB201817047D0 (en) 2018-12-05
SG11202103133QA (en) 2021-05-28
US12234227B2 (en) 2025-02-25
CN113272297B (zh) 2024-03-19
AU2019360428A1 (en) 2021-04-29
MX2021004280A (es) 2021-05-31
ES3058587T3 (en) 2026-03-11
AU2019360428B2 (en) 2024-05-09
CN113272297A (zh) 2021-08-17
EP3867248C0 (en) 2025-12-10
US20250115587A1 (en) 2025-04-10
JP7532353B2 (ja) 2024-08-13
EP3867248B1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
JP7532353B2 (ja) Ｈ４アンタゴニスト化合物としてのピラゾール誘導体
US20240316047A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
CN107438607A (zh) 作为fgfr抑制剂的双环杂环
CN113773257A (zh) 用作cdk抑制剂的经过取代的杂环衍生物
KR20150084047A (ko) Trka 키나아제 억제제로서 n-피롤리디닐, n''-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물
EP2933248B1 (en) Novel renin inhibitor
WO2014109414A1 (ja) 含窒素複素環化合物またはその塩
JP2018524331A (ja) ヘテロアリール置換のアミノピリジン化合物
CA2998705A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
TW202321239A (zh) 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
CN120418238A (zh) 新颖苯并咪唑衍生物
CN118591534A (zh) 新颖苯并咪唑吡啶衍生物
AU2019383845A1 (en) Novel tricyclic compound as IRAK4 inhibitor
JP2010540422A (ja) チエノピリミジン化合物類
RU2821516C2 (ru) Пиразольные производные в качестве соединений-антагонистов h4
CN119866338A (zh) 酪氨酸激酶2抑制剂及其用途
JP7671307B2 (ja) Ｈ４アンタゴニスト化合物
RU2837355C1 (ru) Соединения-антагонисты н4
HK40111206A (en) New benzimidazole pyridine derivatives
EP4642535A1 (en) Benzimidazole derivatives useful as sik modulators
HK40040495A (en) Pyrazole derivatives as malt1 inhibitors
HK1255239B (en) Substituted heterocyclyl derivatives as cdk inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R17-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000